SMC accepts promising new therapy which offers a better quality of life to patients with epilepsy
Around 55,000 people in Scotland are currently living with epilepsy. Significant treatment needs remain for those suffering from the treatment-resistant disease.
New hope, however, has been offered to adults in Scotland with uncontrolled focal epilepsy, as the Scottish Medicines Consortium (SMC) has acceptedOntozry(cenobamate) for adults with drug-resistant epilepsy.
Read more at: https://www.pharmatimes.com/news/angelini_pharmas_ontozry_available_for_patients_in_scotland_with_drug-resistant_epilepsy_1387480